Northwell Health Reports | Receives System-wide Echocardiography Accreditation

Northwell Health, New York State’s largest health system, achieved system-wide accreditation for its 63 echocardiography sites from the Intersocietal Accreditation Commission (IAC). Northwell joins the 708 IAC-accredited echocardiography sites within New York State underscoring Northwell’s commitment to excellence in quality patient care at all clinical sites.

All Northwell hospitals are committed to optimizing patient outcomes and safety by standardizing care. The three-year IAC accreditation recognizes a commitment to following national standards, which includes high quality imaging equipment that contributes to better clinical outcomes for patients. Alignment of imaging and procedural protocols reduces a need for repeat studies.

“Achieving accreditation for echocardiography across our entire system is truly impressive,” said Jeffrey Kuvin, MD, chair of the Department of Cardiology. “It’s another example of our focus on patient-centered, high-quality cardiovascular care at every Northwell location.”

Receiving system-wide accreditation for all of Northwell’s echocardiography sites benefits patients who can be confident they will receive the same level of care regardless of where they go within the health system.

IAC, founded by medical professionals, is a nationally recognized accrediting organization. To receive accreditation, Northwell underwent a thorough review of its echocardiography operational and technical processes.

“We applaud Northwell Health for achieving accreditation for their 63 locations offering echocardiography services,” said Mary Lally, IAC’s chief executive officer. “The standardization and optimization of echocardiography services leads to reductions in administrative and financial burden, but most importantly, improved patient care.”

For more information or to book an appointment, call (833) 826-0897 or go to: https://www.northwell.edu/cardiovascular-thoracic-services/cardiology/find-care/treatments/non-invasive-heart-testing

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”